![Jeffrey Hackman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Hackman
Directeur Général chez
FENNEC PHARMACEUTICALS INC.
Fortune : 623 852 $ au 31/05/2026
Profil
Jeffrey S Hackman is currently the Chairman & Chief Executive Officer at Comera Life Sciences, Inc. and the Chief Executive Officer & Director at Fennec Pharmaceuticals, Inc. Previously, he held positions as the Chairman, President & Chief Executive Officer at Comera Life Sciences Holdings, Inc., Chief Operating Officer & Director at Leadiant Biosciences, Inc., Chief Operating Officer & Director at Sigma-tau Healthscience USA, Inc., SVP-US Internal Medicine & Oncology franchise at Shire Plc, Vice President & Head-North America Region at Baxalta US, Inc., and Chief Executive & Operating Officer, Executive VP at Novelion Therapeutics, Inc. He obtained his undergraduate degree from Lycoming College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2026 | 62 825 ( 0,18% ) | 623 852 $ | 31/05/2026 |
Postes actifs de Jeffrey Hackman
| Sociétés | Poste | Début |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Directeur Général | 16/08/2024 |
Comera Life Sciences, Inc.
 Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biologic medicines | Directeur Général | 08/09/2021 |
Anciens postes connus de Jeffrey Hackman
| Sociétés | Poste | Fin |
|---|---|---|
| COMERA LIFE SCIENCES HOLDINGS, INC. | Directeur Général | 31/01/2024 |
| NOVELION THERAPEUTICS INC. | Directeur Général | 20/11/2018 |
Sigma-tau Healthscience USA, Inc.
 Sigma-tau Healthscience USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation | Directeur des opérations | - |
Baxalta US, Inc.
 Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Corporate Officer/Principal | - |
| SHIRE | Corporate Officer/Principal | - |
Formation de Jeffrey Hackman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Fennec Pharmaceuticals, Inc.
 Fennec Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutic products which dedicated to improving the lives of children with cancer who experience hearing loss | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Lycoming College
 Lycoming College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Health Technology |
Baxalta US, Inc.
Baxalta US, Inc. BiotechnologyHealth Technology Engages in the research, development, and manufacture of biopharmaceutical products | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Sigma-tau Healthscience USA, Inc.
Sigma-tau Healthscience USA, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops biologic medicines | Health Technology |
Comera Life Sciences Holdings, Inc.
 Comera Life Sciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines | Health Technology |
